Spheryx
New York, US · Founded 2014 · New York corporation
Spheryx develops Total Holographic Characterization technology for analyzing suspensions at the sub-visible particle level, including detecting protein aggregates and particles in biopharmaceuticals. Its analytical tools serve product development, manufacturing, and quality assurance across industries such as pharmaceuticals, cosmetics, chemicals, industrial fluids, and petroleum products.
BiotechDeep TechHardware
Founders & leadership
DG
David GrierDirector
LP
Laura PhilipsExecutive Officer, Director
Reported raises · per SEC filings
Form D private placements▶$500.4KraisedJan 2026 · 1 investors · OtherRule 506(b)
▶$500.4KraisedJan 2026 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David GrierDirector
- Laura PhilipsExecutive Officer, Director
- Offering amount
- $2.7M
- Amount sold
- $500.4K
- Minimum investment
- $36K
- First sale
- Jan 2026
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$675KraisedApr 2023 · 4 investors · OtherRule 506(b)
▶$675KraisedApr 2023 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Laura PhilipsExecutive Officer, Director
- David GrierDirector
- Offering amount
- $2.8M
- Amount sold
- $675K
- Minimum investment
- $25K
- First sale
- Apr 2023
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$525KraisedDec 2018 · 5 investors · OtherRule 506(b)
▶$525KraisedDec 2018 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David GrierDirector
- Laura PhilipsExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $525K
- Minimum investment
- $50K
- Proceeds to insiders
- $1.3K
- First sale
- Dec 2018
- Incorporated
- Corporation, New York, 2014
- Federal exemptions
- 06b
▶$1MofferedOct 2017 · OtherRule 506(b)
▶$1MofferedOct 2017 · Other
Rule 506(b)Officers, directors & promoters on the filing
- David GrierDirector
- Laura PhilipsExecutive Officer, Director
- Offering amount
- $1M
- Minimum investment
- $50K
- Proceeds to insiders
- $1K
- Incorporated
- Corporation, New York, 2014
- Federal exemptions
- 06b
▶$575.8KraisedOct 2015 · 5 investors · OtherRule 506(b)
▶$575.8KraisedOct 2015 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Laura PhilipsExecutive Officer, Director
- David GrierDirector
- Offering amount
- $1.1M
- Amount sold
- $575.8K
- Minimum investment
- $50K
- Proceeds to insiders
- $1K
- First sale
- Jan 2015
- Incorporated
- Corporation, New York, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.6M |
| National Science Foundation | Phase II | 2016 | $748K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $318.3K |
| National Science Foundation | Phase I | 2015 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.